Company / Capital Returned to Shareholders
Viking Therapeutics, Inc. Capital Returned to Shareholders History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$6.8M
FY2023
5-year range
$6.8M / $6.8M
FY2019-FY2023
Trend
+0.0%
vs FY2022
Sector context
#44 of 52
Health Care
What the data says
Viking Therapeutics, Inc.'s capital returned to shareholders of $7M is lower than 85% of companies in the Health Care sector (FY2023). Improved from $38 to $7M over the past 7 years.
Based on SEC 10-K filings.
$7M in FY2023.
Improved from $38 to $7M over the past 7 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 52This company $6.8M Sector average $1.3B
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2023, capital returned to shareholders increased 0.0% year-over-year.
- Ranks #44 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $6.8M | +0.0% |
| FY2022 | $6.8M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $38 | +1800.0% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026